Entropy Neurodynamics Seeks ASX Quotation for 1.5 Million New Shares

Tryptamine Therapeutics ( (AU:ENP) ) has issued an update.

Entropy Neurodynamics Limited has applied to the Australian Securities Exchange for quotation of 1,500,000 ordinary fully paid shares under its ENP ticker. The new securities, issued on 27 February 2026, expand the company’s quoted share capital and may influence its liquidity and ownership structure, with implications for existing and prospective investors.

The application, lodged as a new announcement on 2 March 2026, confirms the formal listing of these additional shares in accordance with ASX Listing Rules. By increasing its pool of tradable equity, the company positions itself to potentially support future capital-raising initiatives and enhance its presence in the public markets.

The most recent analyst rating on (AU:ENP) stock is a Sell with a A$0.03 price target. To see the full list of analyst forecasts on Tryptamine Therapeutics stock, see the AU:ENP Stock Forecast page.

More about Tryptamine Therapeutics

Entropy Neurodynamics Limited is a listed company on the Australian Securities Exchange under the code ENP. The company issues ordinary fully paid shares and operates within the capital markets framework governed by ASX Listing Rules, indicating a focus on raising equity through publicly quoted securities.

Average Trading Volume: 2,449,859

Technical Sentiment Signal: Sell

Current Market Cap: A$54.87M

See more data about ENP stock on TipRanks’ Stock Analysis page.